Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial.

ABSTRACT:

Importance

Morphine is used as palliative treatment of chronic breathlessness in patients with advanced chronic obstructive pulmonary disease (COPD). Evidence on respiratory adverse effects and health status is scarce and conflicting.

Objective

To assess the effects of regular, low-dose, oral sustained-release morphine on disease-specific health status (COPD Assessment Test; CAT), respiratory outcomes, and breathlessness in patients with COPD.

Interventions

Participants were randomly assigned to 10 mg of regular, oral sustained-release morphine or placebo twice daily for 4 weeks, with the possibility to increase to 3 times daily after 1 or 2 weeks.

Design, setting, and participants

The Morphine for Treatment of Dyspnea in Patients With COPD (MORDYC) study was a

SUBMITTER: Verberkt CA 

PROVIDER: S-EPMC7432282 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature